Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle, Callaghan, New South Wales, Australia.
PLoS One. 2011;6(8):e23127. doi: 10.1371/journal.pone.0023127. Epub 2011 Aug 4.
Epigenetic regulation of genes involves the coordination of DNA methylation and histone modifications to maintain transcriptional status. These two features are frequently disrupted in malignancy such that critical genes succumb to inactivation. 5-aza-2'-deoxycytidine (5-aza-dC) is an agent which inhibits DNA methyltransferase, and holds great potential as a treatment for cancer, yet the extent of its effectiveness varies greatly between tumour types. Previous evidence suggests expression status after 5-aza-dC exposure cannot be explained by the DNA methylation status alone.
We sought to identify chromatin changes involved with short and long term gene reactivation following 5-aza-dC exposure. Two colorectal cancer cell lines, HCT116 and SW480, were treated with 5-aza-dC and then grown in drug-free media to allow DNA re-methylation. DNA methylation and chromatin modifications were assessed with bisulfite sequencing and Chromatin Immuno-Precipitation analysis.
Increased H3 acetylation, H3K4 tri-methylation and loss of H3K27 tri-methylation were associated with reactivation. Hypermethylated genes that did not show increased acetylation were transiently expressed with 5-aza-dC treatment before reverting to an inactive state. Three reactivated genes, CDO1, HSPC105 and MAGEA3, were still expressed 10 days post 5-aza-dC treatment and displayed localised hypomethylation at the transcriptional start site, and also an increased enrichment of histone H3 acetylation.
These observations suggest that hypomethylation alone is insufficient to reactivate silenced genes and that increased Histone H3 acetylation in unison with localised hypomethylation allows long term reversion of these epigenetically silenced genes. This study suggests that combined DNA methyltransferase and histone deacetylase inhibitors may aid long term reactivation of silenced genes.
基因的表观遗传调控涉及 DNA 甲基化和组蛋白修饰的协调,以维持转录状态。这两个特征在恶性肿瘤中经常被破坏,以至于关键基因失活。5-氮杂-2'-脱氧胞苷(5-aza-dC)是一种抑制 DNA 甲基转移酶的药物,具有很大的治疗癌症的潜力,但在不同肿瘤类型中的疗效差异很大。先前的证据表明,5-aza-dC 暴露后的表达状态不能仅用 DNA 甲基化状态来解释。
我们试图确定 5-aza-dC 暴露后短期和长期基因重新激活所涉及的染色质变化。用 5-aza-dC 处理两种结肠癌细胞系 HCT116 和 SW480,然后在无药物的培养基中培养,以允许 DNA 再甲基化。用亚硫酸氢盐测序和染色质免疫沉淀分析评估 DNA 甲基化和染色质修饰。
H3 乙酰化、H3K4 三甲基化和 H3K27 三甲基化的增加与重新激活有关。未显示增加乙酰化的高甲基化基因在用 5-aza-dC 处理后短暂表达,然后恢复到非激活状态。三个重新激活的基因 CDO1、HSPC105 和 MAGEA3,在 5-aza-dC 处理 10 天后仍有表达,并在转录起始位点显示局部低甲基化,同时组蛋白 H3 乙酰化增加。
这些观察结果表明,单独的低甲基化不足以重新激活沉默的基因,并且与局部低甲基化一起增加组蛋白 H3 乙酰化允许这些表观遗传沉默基因的长期逆转。本研究表明,联合使用 DNA 甲基转移酶和组蛋白去乙酰化酶抑制剂可能有助于沉默基因的长期重新激活。